NetScientific PLC GlycotestT Completes Diagnostic Evaluation (8997A)
January 04 2018 - 1:00AM
UK Regulatory
TIDMNSCI
RNS Number : 8997A
NetScientific PLC
04 January 2018
NetScientific plc
("NetScientific" or the "Company" or the "Group")
Glycotest(TM) Successfully Completes Clinical Diagnostic
Evaluation in Liver Cancer
London, UK - 04 January 2018 - NetScientific plc (AIM:NSCI), the
transatlantic healthcare IP commercialisation group, announces that
its portfolio company Glycotest has successfully completed a
clinical evaluation of its diagnostic panel to detect
Hepatocellular Carcinoma (HCC), the most common form of liver
cancer, in China.
In a blind evaluation of 149 HCC positive patients and control
samples, Glycotest's HCC Panel achieved an AUROC* of 0.97 and
exhibited 93% sensitivity** at 92% specificity***, which indicates
a high predictability on a statistical basis as to whether liver
cancer is present in patients or not.
In the cohort of HCC patients whose tumors had not been detected
by an alpha-fetoprotein (AFP) blood test, the most common blood
test used for initial liver cancer diagnosis, the HCC Panel was
able to identify 86% of patients with liver cancer. In an
early-stage cohort of patients with HCC, the HCC Panel was able to
identify 78% of patients with liver cancer undetected by AFP.
NetScientific holds an 87.5% stake (67% on a fully diluted
basis) in Glycotest.
Commenting on the news, NetScientific's Chief Executive Officer
and Chairman of Glycotest, Francois R. Martelet said: "We are
delighted to announce the success of the Chinese clinical trial,
which validates the previous clinical studies performed with a
combined total of 335 patients. Given that liver cancer is the
fastest growing cause of death in the US and the leading cause of
death in China, we believe that the positive outcome of the trial
will be very significant for patients suffering with HCC.
Commercially, we believe the opportunity to be very attractive,
with an estimated total accessible market of $1bn annually."
The full text of the announcement from Glycotest can be found
below.
For more information please contact:
NetScientific
François R. Martelet, M.D., CEO
Ian Postlethwaite, CFO
Tel: +44 (0)20 3514 1800
info@netscientific.net
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson /
Chris Welsh / Laura Thornton
Tel: +44 (0)20 3709 5700
netscientific@consilium-comms.com
Stifel Nicolaus Europe Limited (NOMAD and Broker)
Jonathan Senior / David Arch / Ben Maddison
Tel: +44 (0) 20 7710 7600
Glycotest Inc.
Lawrence Cohen
Office: +1 646 722 4339
larry.cohen@glycotest.com
About NetScientific:
NetScientific is an IP commercialisation group focused on
healthcare with an investment strategy focused on sourcing, funding
and commercialising technologies that significantly improve the
health and well-being of people with chronic diseases. For more
information, please visit the website at www.netscientific.net
Glycotest(TM) HCC Panel Completes Successful Clinical Product
Evaluation
New York, NY - 04 January 2018 - Glycotest Inc., announced today
that it successfully completed a clinical evaluation of its HCC
Panel in China. In a blinded evaluation of 149 HCC patient and
control samples, the HCC Panel achieved an AUROC of 0.97.
Glycotest is a private liver disease diagnostics company
commercializing new and unique blood tests for liver cancers and
fibrosis-cirrhosis. The Company's mission is to reduce mortality
and increase survival for the growing population at risk from
serious liver diseases, including hepatocellular carcinoma or HCC,
the most common form of liver cancer. Glycotest employs unique
non-invasive blood tests based on proprietary serum biomarkers,
biomarker panels and assay technology that exploit novel
sugar-based disease signal chemistry.
The HCC Panel exhibited 93% sensitivity at 92% specificity in
this product evaluation. In addition, in the AFP-negative cohort,
the HCC Panel achieved an AUROC of 0.93 and identified 86% of the
HCC patients undetected by AFP. In an early-stage HCC cohort, the
HCC Panel achieved an AUROC of 0.96 and identified 78% of the HCC
patients undetected by AFP. Glycotest's proprietary HCC Panel blood
test utilizes three novel fucosylated biomarkers along with three
standard biomarkers and patient demographic data that are converted
to a composite score by a proprietary algorithm. The HCC Panel
score is intended to be used by a patient's physician to determine
the likelihood that the patient has HCC. The effective
identification of patients with AFP-negative and/or potentially
curable early-stage HCC are significant clinical needs unmet by
currently available HCC tests.
In three separate clinical studies involving over 480 patients,
the HCC Panel has now demonstrated the ability to identify
AFP-negative and potentially curable early-stage HCC more
effectively than AFP, the currently dominant blood test for HCC.
Professor Anand Mehta, SmartState Endowed Chair of Proteomic
Biomarkers at the Medical University of South Carolina and one of
the innovators of the Glycotest HCC Panel, said, "It is gratifying
to see that the clinical performance of the HCC Panel for the
identification of patients with potentially curable early-stage HCC
as well as those missed by AFP remains consistently high and
superior to AFP in three separate clinical studies. The HCC Panel
could have a profound impact on the lives of the growing number of
patients who will develop HCC as a consequence of their underlying
viral or non-viral hepatitis."
###
About Glycotest, Inc.
Glycotest is a private liver disease diagnostics company
commercializing novel clinical laboratory testing services for
patients at risk for liver cancers and fibrosis-cirrhosis. The
Company was founded in 2012 on proprietary technology that
originated at the Philadelphia area institutions Baruch S. Blumberg
Institute and Drexel University College of Medicine. Learn more at
www.glycotest.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESEAKFDESFPEFF
(END) Dow Jones Newswires
January 04, 2018 02:00 ET (07:00 GMT)
Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2024 to May 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From May 2023 to May 2024